These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 28612964)

  • 1. Has cost inhibited the uptake of more potent statins in England?
    Chapman SR; Fitzpatrick RW; Aladul MI
    Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):984-991. PubMed ID: 28612964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial.
    Hirsch M; O'Donnell JC; Jones P
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):18-28. PubMed ID: 15703502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Statin's cost-effectiveness: a Canadian analysis of commonly prescribed generic and brand name statins.
    Tran YB; Frial T; Miller PS
    Can J Clin Pharmacol; 2007; 14(2):e205-14. PubMed ID: 17556788
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of recent reforms in Austria on utilization and expenditure of PPIs and lipid-lowering drugs: implications for the future.
    Godman B; Burkhardt T; Bucsics A; Wettermark B; Wieninger P
    Expert Rev Pharmacoecon Outcomes Res; 2009 Oct; 9(5):475-84. PubMed ID: 19817531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generic atorvastatin, the Belgian statin market and the cost-effectiveness of statin therapy.
    Simoens S; Sinnaeve PR
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):49-60. PubMed ID: 23242669
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Do newly marketed generic medicines expand markets using descriptive time series analysis and mixed logit models? Korea as an exemplar and its implications.
    Kwon HY; Godman B
    BMC Health Serv Res; 2016 Apr; 16():130. PubMed ID: 27080530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Statin cost-effectiveness comparisons using real-world effectiveness data: formulary implications.
    Ohsfeldt RL; Gandhi SK; Fox KM; McKenney JM
    Value Health; 2008 Dec; 11(7):1061-9. PubMed ID: 18489494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expiry of patent protection on statins: effects on pharmaceutical expenditure in Australia.
    Clarke PM; Fitzgerald EM
    Med J Aust; 2010 Jun; 192(11):633-6. PubMed ID: 20528715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Initiatives to enhance the quality and efficiency of statin and PPI prescribing in the UK: impact and implications.
    McGinn D; Godman B; Lonsdale J; Way R; Wettermark B; Haycox A
    Expert Rev Pharmacoecon Outcomes Res; 2010 Feb; 10(1):73-85. PubMed ID: 20121565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quality and efficiency of statin prescribing across countries with a special focus on South Africa: findings and future implications.
    Godman B; Bishop I; Campbell SM; Malmström RE; Truter I
    Expert Rev Pharmacoecon Outcomes Res; 2015 Apr; 15(2):323-30. PubMed ID: 25338546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug use evaluation of statins at Siriraj Hospital, 2008.
    Suwansuksree N; Thamlikitkul V; Yamwong P
    J Med Assoc Thai; 2010 Jan; 93 Suppl 1():S179-86. PubMed ID: 20364573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generic and therapeutic statin switches and disruptions in therapy.
    Chapman RH; Benner JS; Girase P; Benigno M; Axelsen K; Liu LZ; Nichol MB
    Curr Med Res Opin; 2009 May; 25(5):1247-60. PubMed ID: 19344292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple initiatives continue to enhance the prescribing efficiency for the proton pump inhibitors and statins in Scotland.
    Bennie M; Godman B; Bishop I; Campbell S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):125-30. PubMed ID: 22280202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of generics and generic reference pricing on candesartan and rosuvastatin utilisation, price and expenditure in South Africa.
    de Jager H; Suleman F
    Int J Clin Pharm; 2019 Feb; 41(1):81-87. PubMed ID: 30478491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 10-year trends in statin utilization in Taiwan: a retrospective study using Taiwan's National Health Insurance Research Database.
    Hsieh HC; Hsu JC; Lu CY
    BMJ Open; 2017 May; 7(5):e014150. PubMed ID: 28515189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Cost-Benefit Balance of Statins in Hawai'i: A Moving Target.
    Lum CJ; Nakagawa K; Shohet RV; Seto TB; Taira DA
    Hawaii J Med Public Health; 2017 Apr; 76(4):99-102. PubMed ID: 28428922
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and cost-effectiveness of rosuvastatin, atorvastatin, and simvastatin among high-risk patients in usual clinical practice.
    Ohsfeldt RL; Gandhi SK; Fox KM; Stacy TA; McKenney JM
    Am J Manag Care; 2006 Nov; 12(15 Suppl):S412-23. PubMed ID: 17112329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pattern of statins' utilization at Ramathobodi Hospital, 2005 to 2007.
    Pattanaprateep O; Pongcharoensuk P; Suvanakoot P; Kaojarern S
    J Med Assoc Thai; 2010 Oct; 93(10):1223-31. PubMed ID: 20973328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective.
    Benner JS; Smith TW; Klingman D; Tierce JC; Mullins CD; Pethick N; O'Donnell JC
    Value Health; 2005; 8(6):618-28. PubMed ID: 16283862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.